NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,144 | -99.9% | 314,762 | 0.0% | 0.31% | +5.1% |
| Q1 2023 | $2,795,087 | -19.1% | 314,762 | 0.0% | 0.29% | -31.3% |
| Q4 2022 | $3,456,087 | -15.7% | 314,762 | 0.0% | 0.43% | -16.1% |
| Q3 2022 | $4,101,000 | +2.8% | 314,762 | 0.0% | 0.51% | +10.4% |
| Q2 2022 | $3,988,000 | -9.6% | 314,762 | 0.0% | 0.46% | +3.8% |
| Q1 2022 | $4,410,000 | -51.6% | 314,762 | 0.0% | 0.44% | -48.0% |
| Q4 2021 | $9,112,000 | -3.4% | 314,762 | 0.0% | 0.86% | +54.6% |
| Q3 2021 | $9,430,000 | +12.9% | 314,762 | 0.0% | 0.55% | +15.0% |
| Q2 2021 | $8,351,000 | -14.7% | 314,762 | 0.0% | 0.48% | -12.1% |
| Q1 2021 | $9,786,000 | -5.4% | 314,762 | 0.0% | 0.55% | -2.5% |
| Q4 2020 | $10,349,000 | -5.8% | 314,762 | 0.0% | 0.56% | -7.1% |
| Q3 2020 | $10,988,000 | – | 314,762 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
| TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
| Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
| Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
| DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
| Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
| Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
| WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
| Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |